Spotlight On... Sanofi poaches Novartis exec Nathwani as new CMO; Epizyme CEO maps 5-year plan; CRISPR recruits a CFO; and more...

New Sanofi ($SNY) CEO Olivier Brandicourt is assembling his top team. The pharma giant announced that Novartis ($NVS) vet Ameet Nathwani has been named EVP and group chief medical officer, earning a seat on the executive committee. Nathwani is taking the place of Paul Chew, who's retiring later in the year. Sanofi has been setting the stage for a reorganization. Release

@FierceBiotech: Strike 3: Struggling Xoma jettisons its lead drug after (another) PhIII failure. News | Follow @FierceBiotech

@JohnCFierce: Sarepta has a new date with an FDA AdCom for Duchenne drug eteplirsen. Article | Follow @JohnCFierce

> Epizyme ($EPZM) CEO Robert Bazemore mapped out a 5-year plan for the company, including the development of tazemetostat. Release

> CRISPR Therapeutics has named Marc Becker as its new CFO. He had been the CFO at rEVO Biologics. Release

> Germany's Evotec achieved a preclinical milestone for the work it's doing for Padlock Therapeutics. Release

Medical Device News

@FierceMedDev: BD forms $500M JV with private equity firm Apax to house ailing respiratory biz. More | Follow @FierceMedDev

@VarunSaxena2: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement. Story | Follow @VarunSaxena2

@EmilyWFierce: Biopharma, Republicans and doctors dig in for fight against new CMS cancer-drug cuts. Article | Follow @EmilyWFierce

> Theranos rival HealthTell raises $26M to support its drop-of-blood diagnostics. More

> Abbott to launch 1,000+ patient trial to standardize traumatic brain injury testing. Story

Pharma News

@FiercePharma: Ceva makes strides toward animal health dominance with strong 2015 sales. More | Follow @FiercePharma

@EricPFierce: More biologics manufacturing capacity comes online in the US. Story | Follow @EricPFierce

@CarlyHFierce: AbbVie's $595M anti-inflammatory deal promises an even bigger battle for psoriasis share. News | Follow @CarlyHFierce

> In a welcome, surprising reversal, pharma's reputation among patients takes an upturn. Story

> Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes. Report

CRO News

> 'Molecule to blame' in fatal French drug study. More

> Icon teams up with a nonprofit to help drive better patient outcomes. Report

> Data collection firm ERT is changing private equity hands. Story

> Swiss CRO PSI stretches its reach into Israel. Article

Pharma Manufacturing News

> Merck hands top manufacturing job to Sanat Chattopadhyay. Report

> Lupin finishes Gavis buy, giving it U.S. manufacturing beachhead. Story

> Bain-backed compounder QuVa gets slapped by FDA for plant failings. Article

> Pfizer expanding API plant in Australia. Item

Pharma Asia News

> Price pressure on drug sales in China accelerates in 2016. Report

> Japan's AMED names 8 projects for pre-designation orphan review. Item

> Carlyle-backed Meinian Onehealth snaps up Ciming for $415M. Story

> China FDA approves Roche's cervical test CINtec. More

> Challenged Benitec moves to get word out on hep B candidate. Article

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.